174 related articles for article (PubMed ID: 9112292)
1. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
[TBL] [Abstract][Full Text] [Related]
2. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C.
Mizokami M; Orito E; Gibo Y; Suzuki K; Ohba K; Ohno T; Lau JY
Liver; 1996 Feb; 16(1):23-7. PubMed ID: 8868074
[TBL] [Abstract][Full Text] [Related]
3. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
4. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
[TBL] [Abstract][Full Text] [Related]
5. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
[TBL] [Abstract][Full Text] [Related]
6. Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response.
Hanley JP; Jarvis LM; Andrew J; Dennis R; Hayes PC; Piris J; Lee R; Simmonds P; Ludlam CA
Blood; 1996 Mar; 87(5):1704-9. PubMed ID: 8634415
[TBL] [Abstract][Full Text] [Related]
7. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
[TBL] [Abstract][Full Text] [Related]
8. Patterns of hepatitis C viremia in patients receiving hemodialysis.
Umlauft F; Gruenewald K; Weiss G; Kessler H; Urbanek M; Haun M; Santner B; Koenig P; Keeffe EB
Am J Gastroenterol; 1997 Jan; 92(1):73-8. PubMed ID: 8995941
[TBL] [Abstract][Full Text] [Related]
9. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
[TBL] [Abstract][Full Text] [Related]
10. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
[TBL] [Abstract][Full Text] [Related]
11. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
12. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
Bekkering FC; Brouwer JT; Leroux-Roels G; Van Vlierberghe H; Elewaut A; Schalm SW
J Hepatol; 1998 Jun; 28(6):960-4. PubMed ID: 9672170
[TBL] [Abstract][Full Text] [Related]
13. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
[TBL] [Abstract][Full Text] [Related]
15. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
Shindo M; Arai K; Okuno T
J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
[TBL] [Abstract][Full Text] [Related]
18. Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.
Bjøro K; Krarup H; Bell H; Christophersen P; Evensen S; Frøland SS; Laursen A; B vd Lippe B; Maeland A; Ranek L
Scand J Gastroenterol; 1995 Nov; 30(11):1119-24. PubMed ID: 8578174
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
[TBL] [Abstract][Full Text] [Related]
20. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
